Biotech news for Wednesday, June 17, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Maddie Meyer/Getty Images News Moderna ( MRNA ) on Tuesday said that Ester Banque, a former senior executive at Zoetis ( ZTS ) and Bristol Myers ( BMY ), will join the company as chief commercial officer as part of organizational changes aiming for upcoming pr…
PTC Therapeutics ( PTCT ) priced a private offering of $500M aggregate principal amount of 0% convertible senior notes due 2031, with an option for initial purchasers to buy an additional $50M of notes. The sale of the notes is expected to
Alvotech ( ALVO ) priced its previously announced underwritten public offering of 22.67M ordinary shares at $3.75 per share, expecting to raise about $85M in gross proceeds. The global biosimilars developer also granted underwriters a 30-day option to purchase…
MicroStockHub/iStock via Getty Images The US FDA has accepted for review an application from Gilead Sciences ( GILD ) for a once-weekly pill version of Yeztugo ( lenacapavir) for pre-exposure prophylaxis (PrEP) of HIV. The sNDA has an FDA action date of Feb. 2…
Alvotech ( ALVO ) announced on Monday it has launched an underwritten public offering of ordinary shares, with a 30-day option period for underwriters to buy up to 15% additional shares at the same offering price. The company will also run
DNY59/iStock via Getty Images A CMS proposed rule that would make permanent drug price negotiations for Medicare has led drugmakers Merck ( MRK ), Johnson & Johnson ( JNJ ), and Bristol Myers Squibb ( BMY ) into the red Monday. The proposal, unveiled on Ju…
Elicio Therapeutics ( ELTX ) is down ~72% in Monday trading after reporting phase 2 data for its pancreatic ductal adenocarcinoma candidate that missed its pre-specified primary endpoint of disease-free survival in an intent-to-treat population. However, the c…
The US FDA has accepted for review Inhibrx Biosciences' ( INBX ) BLA for ozekibart to treat unresectable or metastatic conventional chondrosarcoma. The application has an action date of April 14, 2027. There are currently no FDA-approved therapies for the rare…
Immuneering ( IMRX ) said on Monday it had appointed Andrew Gengos as CFO, effective July 16, 2026. Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals, which was acquired by Merck for $6.7B. Gengos brings experience a…
sei Biotherapeutics ( SNSE ) has changed its corporate name to Faeth Therapeutics. The company’s common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol “FTH” on June 16, 2026. The company has launched a new corporate…
Tiziana Life Sciences ( TLSA ) announced on Monday that its executive chairman and founder, Gabriele Cerrone , through Panetta Partners — an entity in which he has a beneficial interest — has increased his holdings with the purchase of 15,000 common shares at…
CEL-SCI Corporation ( CVM ) slides 7.4% in premarket after pricing its "best-efforts" public offering of 2.5M shares of common stock at $1.00 per share. The company expects to bring in $2.5M in total gross proceeds from the raise, before factoring in placement…